Cancer ovarian treatment
Knowing that the diagnosis age for a significant proportion of patients is above 65 years old, for a proper therapeutic conduct and in order to avoid treatment interruptions caused by toxicity, it was attempted the adjustment of the initial protocole.
In conclusion, the weekly therapeutic scheme is much better tolerated by patients, with a favorable therapeutic response.
Keywords ovarian cancer, fragile age, toxicity, comorbidities Rezumat Vârsta înaintată a pacientelor diagnosticate cu cancer ovarian avansat prezintă un impact major asupra prognosticului, întrucât tratamentul standard de primă linie, carboplatin-paclitaxel administrate la fiecare trei săptămâni, este deseori greu de tolerat din cauza efectelor secundare pronunţate, conducând la pierderea intensităţii dozei sau chiar la întreruperea tratamentului.
[Liver metastases with unknown primary site].
Ştiind că vârsta de diagnosticare pentru un procent semnificativ de paciente este mai mare de 65 de ani, pentru o conduită cancer ovarian treatment adecvată şi pentru a evita amânările tratamentului datorate toxicităţilor, s-a încercat adaptarea protocolului cancer ovarian treatment. În concluzie, schema de administrare săptămânală este mult mai bine tolerată de paciente, cu un răspuns terapeutic favorabil.
Cuvinte cheie cancer ovarian vârstă fragilă toxicitate comorbidităţi Ovarian cancer is the main cause of death by gynecological tumors in Europe.
This combination has a high rate of adverse effects in the general population, such as fatigability, hematological and neurological toxicities, which in elderly patients more than 70 years old can be considered unacceptable, leading to the premature discontinuation of treatment, age itself being considered an unfavorable prognosis factor 3.
In the past 12 years, many studies and clinical trials tried to assess the possibility of administering a tailor-made therapy in elderly patients diagnosed with advanced stage ovarian cancer.
For this category of patients, the standard treatment can induce cancer ovarian treatment increased toxicity risk, thus other options can be used in current practice.
Cancer ovarian - Wikipedia Cancer ovarian treatment, [Liver metastases with unknown primary site].
One of the possibilities is the monotherapy with carboplatin. The result were interpreted as follows.
The Ultimate Guide to Ovarian Cancer, Benedict B. Benigno (Author) - parohiaorsova.ro
Base on this score, there were identified the patients at risk for developing severe toxicities, the direct consequence being the early discontinuation of the treatment, repetead unplanned hospitalizations, and the aggravation of associated pathologies.
Geriatric vulnerability scale The phase II multicentric MITO-5 study analyzed the tolerability of combined paclitaxel-carboplatin therapy with an weekly administration in patients with fragile age, between January and Mayin a number of 26 patients cancer ovarian treatment. The carboplatin dose was cancer ovarian treatment according to Calvert formula 6administered in ml of normal saline, in 30 minutes.
The geriatric aspect was assessed using ADL and IADL, all comorbidities being noted, the main ones being arterial hypertension, diabet mellitus, osteoporosis and arthritis. Table 1.
Patients compliance to treatment The final results were positively reported to the study design, only three cases of severe toxicity being described out of the 26 treated patients one case of atrial fibrillation in an already diagnosed patient with congestive heart failure, a case of grade-3 hepatic toxicity, and a case of neutropenia and prolonged trombocytopenia.
The Ultimate Guide to Ovarian Cancer, Benedict B. Benigno (Author)
The estimated median of progression-free survival was In conclusion, the weekly administration had a more reduced toxic profile compared to standard treatment scheme, which makes this treatment adjustment more appropriate for fragile patients diagnosed with advanced ovarian cancer. What does the future hold for? Study arm B: carboplatin in monotherapy AUC 5 or 6, in every three weeks. As secondary outcome, there are analyzed: the therapeutic stategies, the overall survival, the progression-free survival, the quality of life, the safety and tolerability, and markers related to age.
The results of the study will be published in Conflict of interests: The cancer ovarian treatment declares no conflict of interests. Survival for ovarian cancer in Europe: the across-country variation did not cancer ovarian treatment in the past decade.
Cancer ovarian treatment, [Liver metastases with unknown primary site].
Acta Oncol. Gynecologic Oncology Group: phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group stdy.
J Clin Oncol.
Лишь полностью почувствовав себя дома, Элвин принялся вызывать друзей.
Должно быть, это и есть самый первый облик города, запечатленный в памяти машин.
Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience.
Но если он все-таки имелся -- самый что ни на есть малейший риск пробуждения чего-то странного и неизведанного, грозящего этому миру, то сейчас у Хедрона был последний Шанс предотвратить Порядок вещей, каким он существовал, вполне устраивал Шута.
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. Crit Rev Oncol Hematol. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a Cancer ovarian treatment prospective trial.
Ann Oncol. Carboplatin dosage: prospect of evaluation of a simple formula based on renal function.
Rustin Cancer ovarian treatment. Use of CA to assess response to new agents in ovarian cancer trials. Dana Lucia Stănculeanu Tratamentul cancerului de sân cuprinde o varietate de agenți chimioterapici, de la clasicele citostatice, precum antraciclinele, ciclofosfamida, ta